All Articles
The participation rate in oncology clinical trials among veterans receiving care within the Department of Veterans Affairs is low, at 2%. Read More ›
We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Virginia F. Borges, MD, MMSc, on the use of abemaciclib as a combination or monotherapy in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. Read More ›
Exposing our organizations to the importance of revenue cycle management (RCM) arms them with knowledge critical to identifying and overcoming obstacles throughout the RCM maze. Read More ›
Even with approved targeted therapies for gastric cancer, many patients are still not receiving targeted therapy. Read More ›
Officials with the FDA have granted traditional approval to pembrolizumab (Keytruda; Merck) with trastuzumab- (Herceptin; Genentech), fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥1. Read More ›
Cabozantinib (Cabometyx; Exelixis, Inc) has been approved by the FDA for use in patients aged >12 years who had previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). Read More ›
On March 28, 2025, the FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto; Novartis) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and who are considered appropriate to delay taxane-based chemotherapy. Read More ›
FDA officials recently approved durvalumab (Imfinzi; AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer. Read More ›
Officials with the FDA recently issued a communication in an attempt to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Read More ›
Despite advances in first-line treatment, long-term prognosis for advanced non–small cell lung cancer (NSCLC) remains poor. Read More ›